Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 416.6 DKK 1.21% Market Closed
Market Cap: 29.7B DKK

EV/EBITDA
Enterprise Value to EBITDA

1.8
Current
-18
Median
5.6
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
1.8
=
Enterprise Value
13.2B DKK
/
EBITDA
7.4B DKK
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBITDA: 13.6
1.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 148.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.7
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.1 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.6
17%
1.2
AU
CSL Ltd
ASX:CSL
14.8
12%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -471.3 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
23.3
2-Years Forward
EV/EBITDA
-303.1
3-Years Forward
EV/EBITDA
71.5